Synthesis of Bcl-2 in response to anthracycline treatment may contribute to an apoptosis-resistant phenotype in leukemic cell lines

Cytometry

Volumn 36, Issue 2, 1999, Pages 140-149

  Durrieu, F ^b,d   Belaud Rotureau, M A ^b   Lacombe, F ^a,c   Dumain, P ^a   Reiffers, J ^c   Boisseau, M R ^a,b   Bernard, P ^a,b   Belloc, F ^a,b  

^a HAUT LÉVÊQUE HOSPITAL   (France)

^b UNIVERSITÉ DE BORDEAUX   (France)

^c CNRS Bordeaux Segalen University   (France)

^d UNIVERSITY OF EDINBURGH   (United Kingdom)

Author keywords

Apoptosis; Bax; Bcl 2; Chemoresistance; Flow cytometry; Leukemic cells

Indexed keywords

ANTHRACYCLINE; ANTISENSE OLIGONUCLEOTIDE; CERAMIDE; CYCLOHEXIMIDE; DACTINOMYCIN; IDARUBICIN; PROTEIN BAX; PROTEIN BCL 2;

ANTIBODY LABELING; APOPTOSIS; ARTICLE; FLOW CYTOMETRY; FLUORESCENCE MICROSCOPE; HUMAN; HUMAN CELL; IMMUNOBLOTTING; LEUKEMIA CELL LINE; MULTIDRUG RESISTANCE; PHENOTYPE; PRIORITY JOURNAL; PROTEIN SYNTHESIS;

EID: 0033152876     PISSN: 01964763     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0320(19990601)36:2<140::AID-CYTO8>3.0.CO;2-P     Document Type: Article

References (62)

1. Raff M. Social control on cell survival and cell death. Nature 1993;356: 397-400.
2. Reed J, Miyashita T, Takayama S, Wang HG, Sato T, Krajewski S, Aimé-Sempé C, Bodrug S, Kitada S, Hanada M. Bcl-2 family proteins: regulators of cell death involved in the pathogenesis of cancer and resistance to therapy. J Cell Biochem 1996;60:23-32.
3. Reed J. Bcl-2 and the regulation of programmed cell death. J Cell Biol 1994;124:1-6.
4. Baffy G, Miyashita T, Williamson J, Reed J. Apoptosis induced by withdrawal of Interleukin-3 (IL-3) from an IL-3-dependant hematopoietic cell line is associated with repartitioning of intracellular calcium and is blocked by enforced Bcl-2 oncoprotein production. J Biol Chem 1993;268:6511-6519.
5. Martin S, Newmeyer D, Mathias S, Farschon D, Wang HG, Reed J, Kolesnick R, Green D. Cell-free reconstitution of Fas-, UV radiation-, and ceramide-induced apoptosis. EMBO J 1995; 14:5191-5200.
6. Miyashita T, Reed J. Bcl-2 oncoprotein blocks chemotherapy-induced apoptosis in a human leukemia cell line. Blood 1993;81:151-157.
7. Nuñez G, London L, Hockenberry D, Alexander M, McKearn J, Korsmeyer S. Deregulated Bcl-2 gene expression selectively prolongs survival of growth factor-deprived hemopoietic cell lines. J Immunol 1990;144:3602-3610.
8. Walton M, Whysong D, O'Connor M, Hockenbery D, Korsmeyer S, Kohn K. Constitutive expression of human Bcl-2 modulates nitrogen mustard and camptothecin induced apoptosis. Cancer Res 1993;53: 1853-1861.
9. Zhang H, Alter N, Reed J, Borner C, Obeid L, Hannun Y. Bcl-2 interrupts the ceramide-mediated pathway. Proc Natl Acad Sci USA 1996;93:5325-5328.
10. Krajewski S, Tanaka S, Takayama S, Schibler M, Fenton W, Reed J. Investigations of the subcellular distribution of the Bcl-2 oncoprotein: residence in the nuclear envelope, endoplasmic reticulum, and outer mitochondrial membrane. Cancer Res 1993;53:4701-4714.
11. Amstrong R, Aja T, Xiang J, Gaur S, Krebs J, Hoang K, Bai X, Korsmeyer S, Karanewsky D, Fritz L, Tomaselli K. Fas-induced activation of the cell death-related protease CPP32 is inhibited by Bcl-2 and by ICE family protease inhibitors. J Biol Chem 1996;271: 16850-16855.
12. Kroemer G. The protooncogene Bcl-2 and its role in regulating apoptosis. Nature Med 1997;3:614-620.
13. Craig R. The BCL-2 gene family. Sem Cancer Biol 1995;6:35-43.
14. Oltvai Z, Milliman C, Korsmeyer S. Bcl-2 heterodimerizes in vivo with a conserved homolog, Bax, that accelerates programmed cell death. Cell 1993;74:609-619.
15. Zhang H, Saeed B, Ng SC. Combinatorial interaction of human Bcl-2 related proteins: mapping of regions important for Bcl-2/Bcl-X-S interaction. Biochem Biophysic Res Comm 1995;208:950-956.
16. Krajewski S, Mai J, Krajewska M, Sikorska M, Mossakowski M, Reed J. Upregulation of Bax protein levels in neurons following cerebral ischemia. J Neurose 1995;15:6364-6376.
17. Yin XM, Oltvai Z, Korsmeyer S. BH1 and BH2 domains of Bcl-2 are required for inhibition of apoptosis and heterodimerization with Bax. Nature 1994;369:321-323.
18. Belloc F, Cotteret S, Labroille G, Schmit V, Jaloustre C, Dumain P, Durrieu F, Reiffers J, Boisseau MR, Bernard P, Lacombe F. Bcr-abl translocation can occur during the induction of multidrug resistance and confers apoptosis resistance on myeloid leukemic cell lines. Cell Death Differ 1997;4:806-814.
19. BoironJM, Belloc F, Montastruc M, Cony-Makhoul P, Dumain P, Marit G, Mahon FX, Puntous M, Lopez F, Lacombe F, Reiffers J. Flow cytometric study of Idarubicin and Daunorubicin accumulation and the effect of Verapamil in leukemic cell lines and fresh cells from patients with acute non-lymphoblastic leukemia. Leukemia Res 1994; 18:313-318.
20. Campos L, Sabido O, Rouault JP, Guyotat D. Effects of BCL-2 antisense oligodeoxynucleotides on in vitro proliferation and survival of normal marrow progenitors and leukemic cells Blood 1994;84:595-600.
21. Reed J, Stein C, Subasinghe C, Haldar S, Croce C, Yum S, Cohen J. Antisense-mediated inhibition of BCL2 protooncogene expression and leukemic cell growth and survival: comparisons of phosphodiester and phosphorothioate oligodeoxynucleotides. Cancer Res 1990;50: 6565-6570.
22. Labroille G, Belloc F, Bilhou-Naber C, Bonnefille S, Bascans E, Boisseau MR, Bernard P, Lacombe F. Cytometric study of intracellular P-gp expression and reversal of drug resistance. Cytometry 1998;32:86-94.
23. Durrieu F, Belloc F, Lacoste L, Dumain P, Chabrol J, Dachary-Prigent J, Morjani H, Boisseau MR, Bernard P, Lacombe F. Caspase activation is an early event in anthracycline-induced apoptosis and allows detection of apoptotic cells before they were ingested by phagocytes. Exp Cell Res 1998;240:165-175.
24. Hanada M, Aimé-Sempé C, Sato T, Reed J. Structure-function analysis of Bcl-2 protein. J Biol Chem 1995;270:11962-11969.
25. Hockenbery D. Bcl-2, a novel regulator of cell death. Bio Assays 1995;17:631-638.
26. Park J, Hockenbery D. Bcl-2, a novel regulator of apoptosis. J Cell Biochem 1996;60:12-17.
27. Guedez L, Suresh A, Tung F, Zucali J. Quantification of resistance to cytosine arabinoside by myeloid leukemic cells expressing Bcl-2. Eur J Hematol 1996;57:149-156.
28. Wang HH, Millan J, Cox A, Der C, Rapp U, Beck T, Zha H, Reed J. R-Ras promotes apoptosis caused by growth factor deprivation via a Bcl-2 suppressible mechanism. J Cell Biol 1995;129:1103-1114.
29. Martin S, Takayama S, McGahon A, Miyashita T, Corbeil J, Kolesnick R, Reed J, Green D. Inhibition of ceramide-induced apoptosis by Bcl-2. Cell Death Differ 1995;2:253-257.
30. Bensi L, Longo R, Vecchi A, Messora C, Garagnani L, Bernadi S, Tamassia MG, Sacchi S. Bcl-2 oncoprotein expression in acute myeloid leukemia Haematologica 1995;80:98-102.
31. Campos L, Rouault JP, Sabido O, Oriol P, Roubi N, Vasselon C, Archimbaud E, Magaud JP, Guyotat D. High expression of bcl-2 protein in acute myeloid leukemia cells is associated with poor response to chemotherapy Blood 1993;81:3091-3096.
32. Campos L, Sabido O, Sebban C, Charrin C, Bertheas MF, Fière D, Guyotat D. Expression of BCL-2 protooncogene in adult acute lymphoblastic leukemia. Leukemia 1996; 10:434-438.
33. Maung Z, MacLean F, Reid M, Pearson A, Proctor S, Hamilton P, Hall A. The relationship between bcl-2 expression and response to chemotherapy in acute leukaemia. Br J Haematol 1994;88:105-109.
34. Porwitt-McDonald A, Ivory K, Wilkinson S, Wheatley K, Wong L, Janossy G. Bcl-2 protein expression in normal human bone marrow precursors and in acute myelogenous leukemia. Leukemia 1995;9: 1191-1198.
35. Delia D, Aiello A, Soligo D, Fontanella E, Melani C, Pezzela F, Pierotti M, Della Porta G. Bcl-2 protooncogene expression in normal and neoplastic human myeloid cells. Blood 1992; 9: 291-1298.
36. Keith F, Bradbury D, Zhu YM, Russel N. Inhibition of bcl-2 with antisense oigonucleotides induces apoptosis and increases the sensitivity of AML blasts to Ara-C. Leukemia 1995;9:131-138.
37. Kitada S, Takayama S, De Riel K, Tanaka S, Reed J. Reversal of chemoresistance of lymphoma cells by antisense-mediated reduction of bcl-2 gene expression. Antisense Res Dev 1994;4:71-79.
38. Vial JP, Belloc F, Dumain P, Besnard S, Lacombe F, Boisseau MR, Reiffers J, Bernard P. Study of the apoptosis induced in vitro by antitumoral drugs on leukaemic cells. Leukemia Res 1997;21:163-172.
39. Tu Y, Xu F, Liu J, Vescio R, Berenson J, Fady C, Lichtenstein A. Upregulated expression of BCL-2 in multiple myeloma cells induced by exposure to doxorubicin, etoposide and hydrogen peroxide. Blood 1996;88:1805-1812.
40. Ito T, Deng X, Carr B, May W. Bcl-2 phosphorylation required for antiapoptotic function. J Biol Chem 1997;272:11671-11673.
41. Sedlak T, Oltvai Z, Yang E, Wang K, Boise L. Thompson C, Korsmeyer S. Multiple Bcl-2 family members demonstrate selective dimerizations with Bax. Proc Natl Acad Sci USA 1995; 2:7834-7838.
42. Gottschalk A, Boise L, Oltvai Z, Accavitti M, Korsmeyer S, Quintans J, Thompson C. The ability of Bcl-XL and Bcl-2 to prevent apoptosis can be differentially regulated. Cell Death Differ 1996;3:113-118.
43. Miyashita T, Krajewski S, Krajewska M, Wang HG, Lin H, Liebermann D, Hoffman B, Reed J. Tumor suppressor gene p53 is a regulator of bcl-2 and bax gene expression in vitro and in vivo. Oncogene 1994;9:1799-1805.
44. Salomons G, Brady H, Verwijs-Janssen M, Van Den Berg J, Hart A, Van Den Berg H, Behrendt H, Hählen K, Smets L. The Bax:Bcl-2 ratio modulates the response to dexamethasone in leukaemic cells and is highly variable in childhood acute leukaemia. Int J Cancer 1997;71: 959-965.
45. Stoetzer O, Nussler V, Darsow M, Gullis E, Pelka-Fleischer R, Scheel U, Willmanns W. Association of bcl-2, bax, bcl-XL and interleukin-1 beta-converting enzyme expression with initial response to chemotherapy in acute myeloid leukemia. Leukemia 1996;10 (Suppl 3):S18-S22.
46. Simon S, Schindler M. Cell biological mechanisms of multidrug resistance in tumors. Proc Natl Acad Sci USA 1994;91:3497-3504.
47. Chapman RS., Whetton AD, Chresta CM, Dive C. Characterisation of drug resistance mediated via the suppression of apoptosis by Abelson protein tyrosinekinase. Mol Pharmacol 1995;48:334-343.
48. Amarante-Mendes GP, Kim CN, Liu L, Huang Y, Perkins CL, Green DR, Bhalla K. Bcr-Abl exerts its antiapoptotic effect against diverse apoptotic stimuli through blockage of mitochondrial release of cytochrome C and activation of caspase-3. Blood 1998;91:1700-1705.
49. Sanchez-Garcia I, Grutz G. Tumorigenic activity of the BCR-ABL oncogenes is mediated by BCL2. Proc Natl Acad Sci USA 1995;92:5287-5291.
50. Sanchez-Garcia, Martin-Zanca D. Regulation of Bcl-2 gene expression by BCR-ABL is mediated by Ras. J Mol Biol 1997;267:225-228.
51. Nishii K, Kabaroswski JH, Gibbons DL, Griffiths SD, Titley I, Wiedemann LM, Greaves MF. BCR-ABL kinase activation confers increased resistance to genotoxic damage via cell cycle block. Oncogene 1996;13:2225-2234.
52. Decaudin D, Geley S, Hirsch T, Castedo M, Marchetti P, Macho A, Kofler R, Kroemer G. Bcl-2 and Bcl-XL antagonize the mitochondrial dysfunction preceding nuclear apoptosis induced by chemotherapeutic agents. Cancer Res 1997;57:62-67.
53. Kluck R, Bossy-Wetzel E, Green D, Newmeyer D. The release of cytochrome c from mitochondria: a primary site for Bcl-2 regulation of apoptosis. Science 1997;275:1132-1136.
54. Yang., Liu X, Bhalla K, Naekyung Kim C, Ibrado AM, Cai J, Peng TI, Jones D, Wang X. Prevention of apoptosis by Bcl-2: release of cytochrome c from mitochondria blocked. Science 1997;275:1129-1132.
55. Chinnaiyan, Orth K, O'Rourke K, Duan H, Poirier G, Dixit V. Molecular ordering of the cell death pathway: Bcl-2 and Bcl-XL function upstream of the CED-3-like apoptotic proteases. J Biol Chem 1996;271:4573-4576.
56. Smyth M, Perry D, Zhang J, Poirier G, Hannuns Y, Obeid L. ICE: a downstream target for ceramide-induced apoptosis and for the inhibitory action of Bcl-2. Biochem J 1996;316:25-28.
57. Tao W, Kurschner C, Morgan J. Modulation of cell death in yeast by the bcl-2 family of proteins. J Biol Chem 1997;272:15547-15552.
58. Casciola-Rosen L, Nicholson D, Chong T, Rowan K, Thornberry N, Miller D, Rosen A. Apopain/CPP32 cleaves proteins that are essential for cellular repair: a fundamental principle of apoptotic death. J Exp Med 1996;183:1957-1964.
59. Cosulich S, Green S, Clarke P. Bcl-2 regulates activation of apoptotic proteases in a cell-free system. Curr Biol 1996;6:997-1005.
60. Ibrado AM, Huang Y, Fang G, Liu L, Bhalla K. Overexpression of Bcl-2 or Bcl-XL inhibits Ara-C induced CPP32/Yama protease activity and apoptosis of human acute myelogenous leukemia HL60 cells. Cancer Res 1996;56:4743-4748.
61. Monney L, Otter I, Olivier R, Ravn U, Mirzasaleh H, Fellay I, Poirier G, Borner C. Bcl-2 overexpression blocks activation of the death protease CPP32/Yama/Apopain. Biochem Biophys Res Com 1996;221:340-345.
62. Renvoize, Roger R, Moulian N, Bertoglio J, Brezard J. Bcl-2 expression in target cells leads to functional inhibition of Caspase-3 protease family in human NK and lymphokine-activated killer cell granule-mediated apoptosis. J Immunol 1997;159:126-134.